The company's proprietary MIND platform is specifically designed to identify novel small molecule therapeutics for difficult targets like GPCRs and previously intractable protein targets. The platform combines key technologies such as QM/MM docking, Water pharmacophore, and binding free energy calculations, surpassing the currently standardized technology to create cost-saving and time-efficient solutions for early drug discovery. Our team includes world-renowned scientists and industry leaders in physics-based computational platforms and machine learning technologies. InCerebro also offers its technology both as drug discovery service and as MIND platform technology to accelerate hit identification and lead optimization. We welcome discussions with partners who are interested in investing, co-developing our pipelines, or integrating our physics and AI-based drug discovery platform.
Company Details
- Employees
- 13
- Founded
- 2019
- Address
- 8층 인세리브로, 녹명빌딩,korea, Republic Of
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://incerebro.com
- Keywords
- Drug Discovery, Small Molecule, quantum-driven approach, physics-based computational platform.
- HQ
- 서울시 강남구 테헤란로10길 8
Incerebro Questions
Incerebro's website is http://incerebro.com
Incerebro's LinkedIn profile is https://kr.linkedin.com/company/incerebro
Incerebro has
13 employees.
View email and phone details for 13
employees at Incerebro.
Incerebro's industry is
Pharmaceutical Manufacturing
Incerebro's top competitors are
Quantumbiosolutions,
Noetik,
3billion,
Calici,
Quandela,
Fortuna Helix,
Lnpsolution,
Standigm,
Norma Inc.,
Atomatrix.
Incerebro's categories are Pharmaceutical Manufacturing
Incerebro's founding year is 2019
